Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mycophenolic Acid · 1 trial · 2 indications
The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. A treated BPAR episode was defined as a biopsy graded IA, IB, IIA, IIB, or III that was treated with anti-rejection therapy. Graft loss was defined as the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis as well as re-transplant.
The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. In the definition of composite efficacy failure, loss to follow-up includes patients who did not experience treated BPAR, graft loss or death on or after day 1 and whose last day of contact was prior to day 316, the start day of the 12 month visit window.
| Arm | Type | Description |
|---|---|---|
| Low-dose Everolimus Group | EXPERIMENTAL | 1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids. The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy. |
| High-dose Everolimus Group | EXPERIMENTAL | 3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids. The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy. |
| Control Group | ACTIVE_COMPARATOR | 1.44 g Mycophenolic Acid (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids. The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy. |
| Name | Type | Description |
|---|---|---|
| Everolimus | DRUG | oral, bis in diem/twice a day (bid) |
| Mycophenolic Acid (MPA) | DRUG | 2 oral capsules of mycophenolic acid 360mg administered bid |
| Cyclosporine A (CsA) | DRUG | CsA dose adjustments were based on CsA trough levels (C0). |
| Basiliximab | DRUG | All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice. |
| Corticosteroids | DRUG | Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol. |
Inclusion Criteria: * Male and female patients of any race between 18 to 70 years old (inclusive) * Patients who gave written informed consent to participate in the study Exclusion Criteria: * Recipients of multi-organ transplantation * Recipients of a primary cadaveric or primary non-human leuco...
Mycophenolic Acid is an investigational small molecule being studied for use in kidney transplantation to prevent graft rejection. It is being evaluated in combination with cyclosporine in kidney transplant recipients. The drug is currently in Phase 3 clinical development and is not yet approved by the FDA.
Mycophenolic Acid is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. Novartis is conducting clinical trials to evaluate the safety and efficacy of this drug in kidney transplant recipients.
Mycophenolic Acid is currently in Phase 3 clinical development for kidney transplantation. It is an investigational drug, meaning it has not yet received FDA approval and is still being studied in clinical trials to determine its safety and effectiveness in preventing graft rejection.
Mycophenolic Acid has one completed Phase 3 clinical trial registered under NCT00251004. This study, titled 'Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients,' enrolled 833 participants in the United States and evaluated the drug's efficacy in preventing graft rejection.
No, Mycophenolic Acid is not the same as everolimus. In the clinical trial NCT00251004, Mycophenolic Acid plus cyclosporine was compared against everolimus plus reduced cyclosporine in kidney transplant recipients. These are two distinct drugs being evaluated for the same indication.